Evaluate the efficacy of neoadjuvant therapy for locally advanced gastric cancer based on imaging

Early Evaluation of Neoadjuvant Treatment of Gastric Cancer Based on Multi-series and Multi-phase CT Using Federated Learning and Artificial Intelligent Techniques

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400091029

Enrollment

Unknown

Registered

2024-10-18

Start date

2023-01-05

Completion date

Unknown

Last updated

2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Interventions

Gold Standard:Surgical pathological biopsy

Index test:Multi-series and Multi-phase CT Using Federated Learning and Artificial Intelligent System

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1) Confirmed by biopsy pathology as gastric cancer; 2) There are multi-phase CT images before neoadjuvant therapy; 3) There is a complete neoadjuvant therapy with standardized procedures and complete clinical information; 4) Multi phase CT evaluation images after the second cycle of neoadjuvant therapy;

Exclusion criteria

Exclusion criteria: 1) Patients without CT images before or after 2 cycles of neoadjuvant therapy; 2) Patients who have not completed a complete cycle of neoadjuvant therapy; 3) Patients with missing imaging or pathological data; 4) Patients with distant metastasis.

Design outcomes

Primary

Measure	Time frame
Accuracy;AUC;	—

Secondary

Measure	Time frame
Sensitivity;Specificity;F1-score;Recall;	—

Countries

China

Contacts

Public ContactBingjiang Qiu

Guangdong Provincial People's Hospital

qiubj1990@163.com+86 136 9179 5314

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026